Compare Johnson & Johnson (JNJ) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Oklo Inc — how do they compare? Johnson & Johnson trades at $260.7 (market cap $626.09B), while Oklo Inc trades at $45.16 (market cap $8.74B). The key difference: Johnson & Johnson is far larger — about 71.6× Oklo Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.
| JNJ | OKLO | |
|---|---|---|
Market Cap | $626.09B | $8.74B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $174.14 |
52-Week Low | $172.78 | $36.84 |
Enterprise Value | $654.37B | $6.28B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
OKLO trades at $45.13, up 1.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $77.07. The company reported its first revenue of $1.2 million in Q2 2026 but posted a wider net loss of $0.28 per share, missing estimates. Key milestones include the Groves reactor achieving criticality, though cash burn remains high with operating cash flow negative $117 million in 2026.
The outlook balances significant growth potential in nuclear energy against substantial execution risks. Analyst sentiment is strongly bullish (77% buy ratings), but investors face risks from persistent losses, high spending, and project delays. The stock's trajectory hinges on successful commercialization of its Aurora reactors by the targeted 2028 startup.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
